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Abstract
Objective. To estimate the health and economic burden of rotavirus gastroenteritis in hos-
pital and outpatient settings in eight Latin American and Caribbean countries (Argentina,
Brazil, Chile, Dominican Republic, Honduras, Mexico, Panama, and Venezuela). 
Methods. An economic model was constructed using epidemiological data from published
articles, national health administration studies, and country-specific cost estimates. For each
of the eight countries, the model estimated the rotavirus outcomes for the 2003 birth cohort
during the first five years of life. The main outcome measures included health care costs, trans-
portation costs, lost wages, and disease burden expressed in disability-adjusted life years. Es-
timates were expressed in 2003 US dollars. All future costs and disability-adjusted life year
estimates were discounted at a rate of 3%. Sensitivity analyses evaluated the impact of specific
variables on the medical cost of treating rotavirus. 
Results. For every 1 000 children born during 2003 in the eight Latin American and
Caribbean countries studied here, we estimated that rotavirus gastroenteritis would result in
an average of 246 outpatient visits, 24 hospitalizations, 0.6 deaths, and US$  7 971 in direct
medical costs during their first five years of life. The incidence of rotavirus-associated outpa-
tient visits and the cost of outpatient visits were predicted to have the largest impact on the
total medical cost per child. 
Conclusions. Rotavirus gastroenteritis is likely to result in substantial disease and economic
burden to health systems in Latin American and Caribbean countries, and the foreseeable bur-
den should be an important consideration in evaluating the cost-effectiveness of vaccination. 
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Rotavirus is the most important
viral cause of acute gastroenteritis in
children under 5 years of age, causing
severe dehydrating diarrhea and vom-
iting in infants and young children
worldwide. In Latin America, it is esti-
mated that rotavirus gastroenteritis is
associated with more than 15 000
deaths in under children under 5 years
of age (1). In addition, several studies
have documented that rotavirus gas-
troenteritis is a common cause of hos-
pitalization in children of this age
group (1–7). A recent review of 28
studies of children hospitalized with
severe diarrhea in Latin America
found that 31% to 38% of those hospi-
talizations were attributed to rotavirus
gastroenteritis (8). 
Although the main impact of rota-
virus gastroenteritis is the morbidity
and mortality it causes in children, in-
formation on the economic burden of
disease can aid decisionmakers in
choosing interventions to improve
health. With the development of rota-
virus vaccines, information on the
economic burden of rotavirus and the
potential costs averted by vaccination
can provide decisionmakers with an
estimate of the net impact of vaccina-
tion on financial resources, either in
the health sector or for society as a
whole.
Few studies have evaluated the eco-
nomic burden imposed by rotavirus
gastroenteritis in Latin America.
Among publications retrieved by a
MEDLINE search of health economic
studies of rotavirus or gastroenteritis
from 1995 to 2005, only one study was
undertaken in Latin America (6). Ac-
cording to this study, the Peruvian
Ministry of Health was estimated to
spend over US$ 2.6 million annually
to treat young children with rotavirus
gastroenteritis (6). 
The purpose of this study was to es-
timate the impact of rotavirus gas-
troenteritis in children on the cost of
direct medical treatment to the health
care system in eight Latin American
and Caribbean countries: Argentina,
Brazil, Chile, the Dominican Republic,
Honduras, Mexico, Panama, and Ven-
ezuela. In addition to health care costs,
nonmedical direct (e.g., transporta-
tion) and indirect costs (e.g., produc-
tivity losses) were also considered.
The results should provide insight into
the reductions that could be achieved
in the disease and economic burden by
preventing rotavirus infection.
METHODS
The estimates provided in this analy-
sis of the cost of rotavirus gastroenteri-
tis to the health care system and soci-
ety were obtained with a generalized
model populated with epidemiological
and cost data for the eight Latin Amer-
ican and Caribbean countries. The
model estimated the expected rota-
virus gastroenteritis-associated health
outcomes and costs during the first five
years of life for the 2003 annual birth
cohort in each country (Figure 1).
Country estimates were based on a
combination of country-specific data
and extrapolation from other countries
for which data were lacking. Simula-
tion techniques were used to calculate
ranges for these estimates. 
The eight countries were selected to
provide estimates for different repre-
sentative settings within Latin Amer-
ica and the Caribbean, so geographic
range and income diversity were con-
sidered in choosing the countries. In-
come levels ranged from a per capita
gross domestic product (GDP) of 2003
US$ 1 001 in Honduras, a lower-
middle-income country, to a per capita
GDP of 2003 US$ 6 121 in Mexico, 
an upper-middle-income country (9).
Larger countries were selected to
cover a significant portion of the Latin
American and Caribbean population.
The availability of epidemiological
data for a specific country was consid-
ered, although it was not a necessary
condition for inclusion. 
The primary perspective for this
analysis was that of society as a whole,
including the direct medical costs, di-
rect nonmedical costs, and indirect
costs associated with medical treat-
ment in formal inpatient and outpa-
tient settings. Direct medical costs in-
cluded the costs of tests, medication,
supplies, facilities, and personnel
needed for treatment. Nonmedical di-
rect costs included the cost of trans-
portation to and from the medical fa-
cility. Indirect costs were based on
caregiver productivity losses that oc-
cur as a result of the child being sick.
The main outcome measures were: 
(1) the health care costs of rotavirus
gastroenteritis during the first five
years of life for an annual birth cohort,
(2) the nonmedical direct and the indi-
rect costs for each cohort, and (3) the
disease burden expressed in disability-
adjusted life years (DALYs). All esti-
mates were based on the expected
events and costs for an annual birth
cohort until 5 years of age, after which
rotavirus infection rarely causes se-
vere morbidity or mortality. Estimates
were expressed in 2003 US$. All future
costs and DALYs estimates were dis-
counted at a rate of 3%.
Estimating disease burden of
rotavirus gastroenteritis
For each country, the epidemiologi-
cal burden of rotavirus gastroenteritis
was estimated for the 2003 birth co-
hort until the age of 5 years. A quanti-
tative model was used to predict the
expected events during the first five
years of life. Predicted estimates were
FIGURE 1. Framework for estimating the health and economic burden of rotavirus gastro-
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modeled over time rather than by di-
rectly following the cohort prospec-
tively in an epidemiological study for
the five-year period. The key out-
comes included hospitalizations, out-
patient visits, and deaths. The risks of
hospitalization, outpatient visit, and
death were based on the cumulative
risk of each event due to acute gas-
troenteritis, and the proportion of
those events associated with rotavirus.
Estimates of the number of events
were calculated based on the 2003
birth cohort size and the estimated age
distribution of each event. 
Hospitalization. The 5-year cumula-
tive risk of hospitalization for ro-
tavirus gastroenteritis was estimated
for each country based on epidemio-
logical data from published articles
and national health administration
studies. Published estimates of hospi-
talization for diarrheal disease and ro-
tavirus gastroenteritis were available
for children under 3 years of age in
Chile (4, 10), and for children under 5
years of age in Venezuela (4, 10). Be-
cause the Chilean study reported the
rotavirus hospitalization rate for chil-
dren under the age of 3 years, the inci-
dence rate was converted to the under-
five rate on the basis of published
estimates (3, 7, 11–13). The 5-year
cumulative risk of hospitalization for
rotavirus in Venezuela was adjusted
since only one-third of the “hospital-
ized cases” reported in the study were
actual admissions for overnight care or
longer.4
The 5-year cumulative incidence of
hospitalization for diarrhea in Ar-
gentina, Brazil, Honduras, and Mexico
was based on national administrative
data (14–18). Because national admin-
istrative data do not include hospital-
izations that occur in the private
health care sector, the rates were ad-
justed to include this sector (5, 18–20).
Data for the incidence of hospitaliza-
tion for diarrhea in the Dominican Re-
public and Panama were unavailable;
therefore, cumulative incidence esti-
mates for the two countries were
based on the mean rate for Argentina,
Brazil, Chile, Honduras, Mexico, and
Venezuela (4, 10, 14–18). 
The total number of hospitalizations
of children under 5 years of age for di-
arrhea recorded by the various sources
was divided by the birth cohort (21) to
obtain the five-year cumulative inci-
dence of hospitalization for diarrhea in
each of the eight countries. The pro-
portion of hospitalizations for rota-
virus infection was based on pub-
lished estimates for Argentina (5),
Brazil (22–28), Chile (4), Mexico (29),
and Venezuela (10). Because pub-
lished estimates were not available for
the Dominican Republic, Honduras,
and Panama, the proportion of hospi-
talizations for diarrhea attributed to
rotavirus for these countries was esti-
mated based on other countries in
Latin America and the Caribbean (4–6,
11, 29). The cumulative risk of hospi-
talization for rotavirus gastroenteritis
was then calculated by multiplying the
cumulative risk of hospitalization for
diarrhea by the proportion attributed
to rotavirus gastroenteritis.
Outpatient visits. The five-year cumu-
lative incidence of outpatient visits for
rotavirus gastroenteritis was estimated
from published and administrative
data. Published estimates of outpatient
visits for rotavirus gastroenteritis were
available in Chile for children under 3
years of age (4) and in Venezuela for
children under 5 years of age (10). The
Chilean data were adjusted to a five-
year risk on the basis of published esti-
mates (30, 31), and were adjusted to in-
clude data regarding nonemergency
visits (32). The incidence of outpatient
visits for rotavirus in Venezuela was
adjusted to include outpatient visits in
nonhospital settings, with data that
were based on interviews with eight
Venezuelan physicians. 
The five-year cumulative incidence
of outpatient visits for diarrhea in Ar-
gentina, Honduras, Mexico, and Pan-
ama was calculated from national ad-
ministrative data (16–18, 33, 34), and
adjusted for inclusion of the private
sector (5, 18, 20, 35). Because data were
unavailable for Brazil and the Domini-
can Republic, the cumulative risk of an
outpatient visit due to diarrhea in
these two countries was based on the
mean risk calculated for Argentina,
Chile, Honduras, Mexico, Panama,
and Venezuela. 
For Brazil, Chile, and Venezuela the
proportion of outpatient visits for di-
arrheal disease attributed to rotavirus
was based on published data (4, 10,
36–39). The proportion of outpatient
visits attributed to rotavirus diarrhea
for the Dominican Republic, Hon-
duras, Mexico, and Panama was based
on extrapolation from other countries
in Latin America and the Caribbean
(4–6, 10, 40). For Argentina, the rota-
virus proportion was based on a pub-
lished study (5) and a personal com-
munication.5 The cumulative risk of an
outpatient visit for rotavirus gastroen-
teritis was calculated by multiplying
the cumulative risk of an outpatient
visit for diarrhea by the proportion at-
tributed to rotavirus gastroenteritis.
Mortality. The five-year cumulative in-
cidence of diarrheal mortality was
based on country-specific estimates,
using ICD-10 categories A00–A09 (41).
National administrative data on deaths
from diarrhea were available for Ar-
gentina, Brazil, Mexico, Panama, and
Venezuela (21, 42–45). Estimates of the
risk of death due to diarrheal disease in
Chile and the Dominican Republic
were based on the WHO Mortality
Database (46). For Honduras, estimates
were based on the Pan American
Health Organization estimate of mor-
tality in children under 5 years of age
(21), and on a national survey estimate
of the proportion attributable to diar-
rhea (47). The five-year cumulative risk
of death due to diarrheal disease was
then calculated by dividing the esti-
mated number of deaths due to diar-
rheal disease in under-five children by
the birth cohort of each country (21).
The cumulative risk of death due to ro-
tavirus gastroenteritis was calculated
by multiplying the risk of death due to
4 Irene Pérez-Schael, Instituto de Biomedicina, Uni-
versidad Central de Venezuela, Ministerio de
Sanidad, Fuvesin, Caracas, Venezuela. Personal
communication, October 2004.
5 Jorge Gómez, Instituto Nacional de Enfermedades
Infecciosas, Buenos Aires, Argentina. Personal
communication, August 2004.
diarrheal disease by the proportion of
deaths from diarrhea attributed to ro-
tavirus. Because no studies estimated
the proportion of deaths from diarrhea
attributed to rotavirus, the proportion
was assumed to be the same as that for
hospitalized cases. 
Disability-adjusted life years. In ad-
dition to estimating the number of
events, the disease burden was also ex-
pressed in terms of DALYs, an index
that makes comparisons with other
diseases possible. The DALYs estimate
includes two components: years of life
lost (YLLs) due to premature mortal-
ity, and years lived with disability
(YLDs). The former was calculated
based on the average country-specific
life expectancy at birth and 1 year of
age (48). To calculate YLDs, only mor-
bidity from a disease severe enough to
require medical care was considered.
This component was calculated from
default disability weights from the
Global Burden of Disease Study (49)
and the World Health Organization’s
guidelines for cost-effectiveness stud-
ies (50), assuming an average duration
of illness of six days (51). Because of
the short duration of illness from
gastroenteritis, YLDs contributed very
little to the DALYs estimate, so the es-
timate was based primarily on the
YLLs. To ensure comparability, a dis-
count rate of 3% and age weighting
were included (49). 
Table 1 summarizes the values used
to calculate the disease burden for ro-
tavirus gastroenteritis. 
Estimating medical costs associated
with rotavirus gastroenteritis
The economic burden of rotavirus
gastroenteritis to the health care sys-
tem in the eight countries was esti-
mated by combining the number of
each type of event with information on
the costs associated with the event.
This information was combined in a
spreadsheet-based decision-analytic
model. For hospital and outpatient
events, these were partitioned into the
cost of the visit (including facilities
and personnel) and the cost of the re-
sources used for treatment (diagnostic
tests and medication). For each coun-
try, baseline estimates were based on
resource use information from a pro-
spective rotavirus surveillance study
and facility-specific cost data. To com-
pare costs among countries, two alter-
native sources of cost estimates were
used: (1) the WHO-CHOICE (Choos-
ing Interventions that are Cost Effec-
tive) project (52) and (2) estimates ob-
tained from physician interviews. 
Prospective rotavirus surveillance
study. Economic cost data were col-
lected as part of an ongoing rotavirus
gastroenteritis surveillance study done
prior to a randomized vaccine trial
(53). The prospective study was con-
ducted in one or more sites in each of
the eight countries. Participating sites
generally consisted of secondary- or
tertiary-level facilities that provided
inpatient and outpatient care to chil-
dren. Eligible cases were children less
than 24 months of age who came to the
center with severe gastroenteritis, de-
fined as an episode of diarrhea (the
passage of three or more loose or wa-
tery stools within a 24-hour period),
with or without vomiting, that re-
quired overnight hospitalization or re-
hydration therapy equivalent to World
Health Organization (WHO) plan B
(oral rehydration therapy) or plan C
(intravenous rehydration therapy), in 
a medical facility such as a hospital,
clinic, or supervised rural health care
center. At each site, economic data
were collected for a sample of approx-
imately 60 inpatients and 60 outpa-
tients. Sample size was determined
based on the recommendation of the
WHO guide to costing diarrheal dis-
ease (54) in order to ensure an esti-
mated mean direct medical cost within
15% of the actual mean. Stool samples
were tested for rotavirus with an
enzyme-linked immunoassay.
Health economic data were col-
lected during 2003. The surveillance
study contained an economic compo-
nent to calculate the direct medical
costs, direct nonmedical costs, and in-
direct costs associated with rotavirus
gastroenteritis. A cost questionnaire
was administered to the caregivers of
patients with gastroenteritis. Ques-
tions asked about nonmedical direct
costs (cost of transporting the child to
the hospital and visiting the child in
the hospital) and indirect costs (time
lost from paid work to care for the
child). Investigators also reported pa-
tient data regarding the length of stay
and the utilization of diagnostics and
medication to treat gastroenteritis. 
Survey data were analyzed using
SAS statistical software (SAS Institute
Inc., Cary, North Carolina, United
States of America). Separate estimates
were generated for inpatients and out-
patients. Inpatients were those who
were classified as inpatients and spent
a minimum of one day in the hospital,
and outpatients were those who were
not classified as inpatients and spent a
maximum of one day at the hospital or
clinic. For countries in which outpa-
tients can stay at the hospital “under
observation” but are not admitted, the
outpatient definition was adapted to
include patients who stayed for more
than one day at the center’s rehydra-
tion facility.
Health care costs were calculated as
the sum of the visit cost at the hospital
or outpatient setting, the cost of diag-
nostics, and the cost of medication. Es-
timates of the hospital per diem costs
were based on information from hos-
pital finance departments of public
health care facilities, with the excep-
tion of Chile since per diem data were
available from private facilities as
well. The cost per stay as an inpatient
was calculated by multiplying the per
diem rate (which includes the cost of
accommodation, administration, food,
and personnel) by the duration of stay
(between three and four days). 
The cost per outpatient visit was cal-
culated as the weighted mean of the
cost of visiting a pediatrician, general
practitioner, emergency room, or rehy-
dration facility based on the propor-
tion of patients seen in each of these
four outpatient settings. This informa-
tion was obtained from physician in-
terviews done in 2003. Health care uti-
lization patterns varied by country;
however, the proportion seen by a pe-
diatrician or in an emergency depart-
ment was generally greater than the
proportion seen by a general practi-
tioner or in a rehydration facility.
Costs for these types of outpatient vis-
its were based on the average costs for
public facilities. 
Mean total diagnostic and medica-
tion costs for treating gastroenteritis
were calculated for both inpatients
and outpatients for each country. The
unit cost for each diagnostic test was
based on estimates provided by the fi-
nance departments of public hospitals,
and costs associated with medications
were based on the listing of medica-
tions and national formularies (55, 56). 
Alternative health care cost estimates.
To compare the findings across coun-
tries, we also estimated inpatient and
outpatient visit costs with a standard-
ized approach developed by WHO for
its WHO-CHOICE project (52) and
data from cost studies of diarrhea (57).
The WHO-CHOICE project provided
estimates of the per-diem and per-visit
cost of public health care facilities for
14 epidemiological categories based
on geographical region and mortality
stratum. The per-diem and per-visit
cost estimates included the cost of the
facility, personnel, equipment, and
food, and excluded the cost of medica-
tions and diagnostic tests (52). Based
on information from cost studies of di-
arrheal disease conducted in Mexico
and the Philippines, we estimated that
these costs would add 33% to the cost
of hospitalization, and 65% to the cost
of outpatient visits (57). 
Because the WHO-CHOICE model
was developed using year-2000 inter-
national dollars, all costs were con-
verted to 2003 US$ using the consumer
price index, purchasing power parity
conversion factors, and official ex-
change rates (9, 58). “International dol-
lars” are used to express the value of a
quantity in a local currency based on
its purchasing power compared to a
US$ rather than the actual exchange
rate. A hospital per-diem rate was esti-
mated for each country as a weighted
average of estimates for public primary-,
secondary-, and tertiary-level facili-
TABLE 1. Input variables and ranges used for estimating the economic burden of rotavirus gastroenteritis for the 2003 birth cohort in eight
Latin American and Caribbean countries 
Dominican
Variable (source) Argentina Brazil Chile Republic Honduras Mexico Panama Venezuela
Birth cohort, 2003 (21) 726 000 3 471 000 286 000 203 000 206 000 2 285 000 70 000 582 000
5-year risk of hospitalization for 
for gastroenteritis (4, 10, 14–18)a 0.093 0.112 0.060 0.065 0.038 0.018 0.065 0.070
Upper and lower boundsb 0.08, 0.11 0.10, 0.13 0.05, 0.07 0.05, 0.08 0.03, 0.04 0.01, 0.02 0.05, 0.08 0.06, 0.08 
Proportion of gastroenteritis 
hospitalizations due to rotavirusa
(4–6, 10, 22–29, 40) 0.34 0.31 0.47 0.37 0.37 0.40 0.37 0.33
Upper and lower bounds 0.29, 0.39 0.26, 0.36 0.40, 0.54 0.30, 0.44 0.30, 0.44 0.34, 0.46 0.30, 0.44 0.28, 0.38 
5-year risk of an outpatient visit 
for gastroenteritis 
(4, 10, 16–18, 33, 34)a 1.38 1.08 0.69 1.08 1.07 1.06 1.13 1.15
Upper and lower boundsb 1.17, 1.59 0.81, 1.35 0.59, 0.79 0.81, 1.35 0.91, 1.23 0.90, 1.22 0.96, 1.30 0.98, 1.32 
Proportion of gastroenteritis 
outpatient visits due to rotavirus 
(4–6, 10, 36–40)a 0.26 0.19 0.34 0.25 0.25 0.25 0.25 0.23
Upper and lower boundsb 0.22, 0.30 0.16, 0.22 0.29, 0.39 0.20, 0.30 0.20, 0.30 0.20, 0.30 0.20, 0.30 0.20, 0.27 
5-year risk of death for gastroenteritis 
(per 1 000 births) (21, 41–45)a 0.40 2.30 0.10 5.90 8.70 1.01 1.44 2.00
Upper and lower boundsb 0.34, 0.46 1.96, 2.65 0.09, 0.12 5.02, 6.79 7.40, 10.01 0.86, 1.16 1.22, 1.66 1.70, 2.30 
Proportion of gastroenteritis deaths 
due to rotavirusc 0.34 0.31 0.47 0.37 0.37 0.40 0.37 0.33
Upper and lower boundsb 0.27, 0.41 0.25, 0.37 0.38, 0.56 0.30, 0.44 0.30, 0.44 0.32, 0.48 0.30, 0.44 0.26, 0.40 
Proportion seen in private sector Data Data 
(4, 5, 18–20, 35) 0.46 0.25 0.27 unavailable 0.12 0.15 0.07 unavailable
Gross domestic product per capita 
(2003 US$) (9) 3 381 2 788 4 591 1 821 1 001 6 121 4 328 3 319
Average life expectancy (years) (47) 74.2 68.9 75.8 69.6 69.1 74.0 74.1 73.8
Mean female hourly wage 
(US$) (59–62) 0.87 1.58 2.11 0.71 0.53 1.86 2.10 1.05
a The shape of the distribution was defined as triangular distribution since the true population value was more likely to be closer to the chosen value for the analysis than the minimum or max-
imum values defined by the range. 
b The upper and lower bounds of the distributions were the ones used in the sensitivity and uncertainty analyses.
c The proportion of gastroenteritis mortality attributable to rotavirus was based on the proportion of hospitalizations attributable to this diagnosis. The shape of the distribution was defined as
uniform since the true population value was equally likely to be any value within the specified range.
ties, using the proportions of each
from the multicountry study (59). The
cost of hospitalization was calculated
as the product of the per-diem cost
and a duration of 3.5 days (6, 60, 61).
Country-specific outpatient visit costs
were calculated by adjusting the WHO-
CHOICE regional estimate propor-
tionally to the country-specific hospi-
tal per-diem cost. 
The second alternative approach
used physician interviews to estimate
resource utilization for the treatment of
rotavirus gastroenteritis, along with
facility- and country-specific unit cost
estimates. Interviews of four to eight
physicians in each country, mostly from
public health settings, were conducted
in 2003 to characterize the typical man-
agement of rotavirus gastroenteritis. In-
terviews included questions regarding
care for patients with moderate ro-
tavirus gastroenteritis, and for patients
with severe rotavirus gastroenteritis.
Estimating societal costs of rotavirus
gastroenteritis
In addition to health care costs, non-
medical direct (e.g., transportation
costs) and indirect costs (e.g., produc-
tivity losses) were also calculated
based on the prospective rotavirus
surveillance study. Caregivers of inpa-
tients and outpatients were asked how
much money they spent to transport
their child or themselves to the health
facility. Caregivers were also asked to
quantify time lost from paid work due
to their child’s illness. The average in-
direct cost was estimated by multiply-
ing the mean hours lost by the mean
female hourly wage for each of the
countries (62–65). 
Uncertainty and sensitivity analyses
Although country-specific data on
the epidemiology of the disease and
the associated health care costs were
available for most countries, the qual-
ity and relevance of the data were lim-
ited for others, a limitation that created
uncertainties regarding the final eco-
nomic burden estimates. Two ap-
proaches were used to address this un-
certainty: sensitivity and uncertainty
analyses. A one-way sensitivity analy-
sis was conducted by varying individ-
ual input parameters by ± 20% to as-
sess their impact on the economic
burden in each country. An uncer-
tainty analysis was conducted to eval-
uate the overall impact of uncertainty
on the estimates, to develop upper and
lower bounds for the estimates, and to
assess the contribution of individual
parameters to overall uncertainty. 
For each country, burden estimates
were calculated in a spreadsheet-
based decision-analytic model that es-
timated the frequency of different
events and the costs associated with
each. A Monte Carlo model was devel-
oped based on this model. In Monte
Carlo analysis, individual point esti-
mates of parameters are replaced with
distributions of potential values (66).
In a series of iterations, individual val-
ues are randomly selected from each
of the distributions, and results are cal-
culated and stored. The process is re-
peated for a large number of iterations
(10 000 in this case). The final product
is a distribution of potential outcomes
that describe the likely range of actual
expected results. 
For national disease burden vari-
ables, distributions were used to char-
acterize the cumulative incidence of
illness outcomes (hospitalization, out-
patient visits, and death) in each coun-
try, and the proportion due to ro-
tavirus. The distributions specified a
range around the value chosen for
analysis, and described the likelihood
that the true population value would
be the value chosen. Wider distribu-
tions were used for countries for
which the estimates were extrapolated
from other countries. For the cost vari-
ables, input distributions were based
on the mean costs and standard errors
from the baseline analysis described
above. Table 1 shows the best esti-
mates and distributions used in the
analysis. 
Upper- and lower-bound uncer-
tainty limits (5% and 95%) were esti-
mated for the key output parameters:
direct medical costs and total societal
costs for each country. In addition, a
contribution-to-variance analysis was
done to determine the contribution of
the individual input parameters to the




In the eight countries together,
which represent 68% of the total an-
nual births in Latin America, rotavirus
gastroenteritis was predicted to be re-
sponsible for approximately 2 000 000
outpatient visits, 190 000 hospitaliza-
tions, and 5 000 deaths for the annual
birth cohort. In each of the countries,
per 1 000 children, rotavirus gastroen-
teritis was predicted to result in 205 to
359 outpatient visits, 7 to 35 hospital-
izations, and 0.05 to 3.2 deaths (Table
2). The DALYs resulting from these
events ranged from 2 to 107 per 1 000
children, with lower rates observed in
higher-income countries due to lower
mortality.
Economic burden
The mean predicted costs (direct
medical, direct nonmedical, and indi-
rect) for hospital and outpatient events
associated with gastroenteritis are
shown in Table 3. In each of the coun-
tries, direct medical costs were esti-
mated to account for the majority of
the total costs of hospitalizations and
outpatient visits. The cost of medica-
tions and diagnostics was expected to
account for 5% to 25% of the medical
costs of hospitalization, and 30% to
75% of the costs of outpatient visits.
The total estimated medical costs per
hospitalization ranged from US$ 72.49
in the Dominican Republic to US$
190.12 in Panama, and the total esti-
mated medical costs per outpatient
visit ranged from US$ 6.54 in the Do-
minican Republic to US$ 33.99 in Chile.
The calculated treatment costs for hos-
pital and outpatient events were con-
sistent with estimates provided by the
two alternative methods (WHO-
CHOICE and physician interviews). 
Table 4 shows the estimated health
care system and societal costs of these
rotavirus-associated events for the
2003 birth cohort in each country, and
upper and lower uncertainty limits for
these estimates. From the health care
system perspective, the average esti-
mated direct medical costs ranged
from US$ 3 400 to over US$ 16 000 per
1 000 births, with higher costs tending
to occur in the higher-income coun-
tries. In all countries except Argentina
and Brazil, where rotavirus hospital-
ization rates are higher, the majority of
the total costs were predicted to result
from outpatient visits. From the soci-
etal perspective, total estimated costs
(including nonmedical and indirect
costs) of rotavirus gastroenteritis
ranged from US$ 5 000 to almost US$
19 000 per 1 000 births. Overall, direct
TABLE 2. The burden of rotavirus gastroenteritis in eight Latin American and Caribbean countries, estimated as the expected number of
events for the 2003 birth cohort during the first five years of life
Dominican
Argentina Brazil Chile Republic Honduras Mexico Panama Venezuela Total
Birth cohort 726 000 3 471 000 286 000 203 000 206 000 2 285 000 70 000 582 000 7 829 000
Events
Hospitalizations 22 956 120 513 8 008 4 882 2 896 16 086 1 684 13 502 190 528
Outpatient visits 260 489 712 249 66 924 54 810 55 105 605 525 19 775 153 648 1 928 525
Deaths 99 2 475 13 443 663 923 37 384 5 038
DALYsa 3 549 83 365 543 14 823 22 120 31 768 1 277 13 098 170 542
Events per 1 000 births
Hospitalizations 32 35 28 24 14 7 24 23 24
Outpatient visits 359 205 234 270 268 265 283 264 246
Deaths 0.1 0.7 0.05 2.2 3.2 0.4 0.5 0.7 0.6
DALYs 5 24 2 73 107 14 18 23 22
a DALYs = disability-adjusted life years.
TABLE 3. Estimated costs in 2003 US dollars of treating rotavirus gastroenteritis in the 2003 birth cohort during the first five years of life
in eight Latin American and Caribbean countries, using prospectively collected cost data and two alternative methods for estimating health
care costs 
Dominican
Argentina Brazil Chile Republic Honduras Mexico Panama Venezuela
Hospitalization No. = 60 No. = 43 No. = 41 No. = 29 No. = 32 No. = 49 No. = 196 No. = 55
Per diem cost 39.67 35.07 41.70 16.64 24.36 50.98 53.00 19.91
Total accommodation costa 142.81 129.76 125.10 66.56 95.00 173.33 153.70 81.63
Diagnostics and medication 20.39 21.21 40.27 5.93 24.75 14.11 36.42 43.31
Total direct medical costs 163.20 150.97 165.37 72.49 119.75 187.44 190.12 124.94
Alternative estimates of direct 
medical costs
Alternative 1b 133.56 123.13 189.74 80.87 57.50 263.53 201.43 164.00
Alternative 2c 194.10 179.16 178.59 78.35 124.07 227.92 163.70 81.70
Transportation 7.12 1.49 12.72 1.99 2.83 7.36 8.99 4.91
Indirect cost 11.57 18.58 18.27 5.43 2.60 21.08 15.81 8.85
Outpatient visit No. = 50 No. = 52 No. = 53 No. = 224 No. = 38 No. = 66 No. = 91 No. = 21
Per visit cost 5.62 5.39 14.01 4.49 5.81 13.30 15.88 5.48
Diagnostics/medication 7.65 5.42 19.98 2.05 15.96 10.86 12.54 17.79
Total direct medical costs 13.27 10.81 33.99 6.54 21.77 24.16 28.42 23.27
Alternative estimates of direct 
medical costs
Alternative 1b 12.06 11.12 17.13 7.31 5.20 23.79 18.18 14.80
Alternative 2c 8.41 12.64 20.13 5.84 12.93 18.51 17.48 9.87
Transportation 0.49 0.04 0.66 2.05 1.95 1.58 3.46 1.55
Indirect cost 2.09 8.35 7.64 4.47 2.26 13.54 9.44 4.10
a Total accommodation cost = per diem cost × average length of stay. For the eight countries, the average length of stay of in days was: Argentina, 3.6; Brazil, 3.7; Chile, 3.0; Dominican Re-
public, 4.0 (based on physician interviews); Honduras, 3.9; Mexico, 3.4 (based on the hospital-based surveillance study and physician interviews); Panama, 2.9; and Venezuela, 4.1.
b Alternative 1, WHO-CHOICE and data from diarrheal cost studies (51).
c Alternative 2, physician interview data obtained in 2003.
medical costs accounted for 73% of the
total estimated cost in the eight coun-
tries. Hospitalization events accounted
for 17% to 70% of direct estimated me-
dial costs, and 12% to 60% of total esti-
mated costs in each country.
Sensitivity and uncertainty
The results of the one-way sensitiv-
ity analysis are shown in Table 5. The
table reports the estimated cost per 
1 000 children in 2003 US$ for each
country, using three scenarios: base-
line, a 20% increase in the selected
value, and a 20% decrease. Compared
to the baseline figures, a 20% increase
or a 20% decrease in rotavirus hospi-
talization or outpatient visit incidence
resulted in a 2% to 12% and an 8% to
18% change in total costs, respectively.
Similarly, a 20% increase or decrease
in average direct medical costs for hos-
pitalization or outpatient visits re-
sulted in a 2% to 11% and a 4% to 13%
change in total costs, respectively.
The results of the uncertainty analy-
ses are shown in Table 4 and Table 6.
Upper and lower uncertainty bounds
are provided in Table 4 for the esti-
mates of direct medical and societal
costs of rotavirus gastroenteritis. The
uncertainty limits were smallest when
country-specific data were available
for estimating key epidemiological
parameters (Argentina, Chile, and
Venezuela). 
The contribution-to-variance analy-
sis summarized in Table 6 examined
the effect of selected input parameters
on the total estimated cost of rotavirus
gastroenteritis in each country. Uncer-
tainty in the incidence of outpatient
visits for diarrhea and the proportion
of these visits ascribed to rotavirus di-
arrhea contributed at least 7% to the
overall uncertainty in the economic
burden for each country, although the
contribution was much higher in
some countries such as the Dominican
Republic, Honduras, Mexico, and
Panama. The incidence of hospitali-
zation for diarrhea and the proportion
of hospitalizations ascribed to ro-
tavirus diarrhea were highest in
Brazil, where these factors accounted
for 16% to 17% of the overall uncer-
tainty. Direct medical costs were a rel-
atively larger source of variability in
countries for which there was more
certainty regarding country-specific
epidemiological inputs (e.g., hospital-
izations in Argentina or Chile, and
outpatient visits in Honduras). Indi-
rect costs for hospitalizations con-
tributed a small fraction to the overall
uncertainty; however, indirect costs
for outpatient visits made larger con-
tributions to overall uncertainty, espe-
cially in Brazil, Mexico, Panama, and
Venezuela.
TABLE 4. The estimated economic burden, in 2003 US$, of rotavirus gastroenteritis in the 2003 birth cohort during the first five years of life
in eight Latin American and Caribbean countries 
Dominican
Argentina Brazil Chile Republic Honduras Mexico Panama Venezuela
Direct medical costs
Hospitalization 3 685 584 17 813 038 2 233 323 346 417 339 574 2 952 068 313 370 1 662 273
Outpatient visit 3 375 524 7 519 460 2 407 961 350 184 1 172 105 14 290 600 549 018 3 491 822
Total 7 061 108 25 332 499 4 641 283 696 601 1 511 679 17 242 669 862 387 5 154 096
Uncertainty range 6 067 380 to 21 765 457 to 3 885 593 to 559 376 to 1 253 134 to 14 595 840 to 732 265 to 4 423 414 to
8 126 045 29 111 179 5 469 498 844 638 1 791 978 19 788 196 1 003 551 5 955 345
Nonmedical direct costs
Hospitalization 160 027 175 807 99 730 9 512 8 025 143 323 14 818 64 910
Outpatient visit 124 677 27 829 43 145 109 752 104 960 2 141 118 66 833 232 626
Total 284 704 203 636 142 875 119 264 112 986 2 284 441 81 651 297 536
Indirect costs
Hospitalization 260 045 2 192 280 137 756 21 175 7 373 332 006 26 059 116 996
Outpatient visit 531 784 5 809 228 480 473 195 413 121 646 8 008 492 182 343 615 334
Total 791 829 8 001 508 618 230 216 588 129 019 8 340 498 208 402 732 330
Total costs
Hospitalization 4 105 656 20 181 125 2 470 809 377 105 354 972 3 427 397 354 247 1 844 179
Outpatient visit 4 031 985 13 356 517 2 931 579 655 349 1 398 712 24 440 211 798 194 4 339 782
Total 8 137 641 33 537 642 5 402 388 1 032 454 1 753 684 27 867 608 1 152 441 6 183 961
Uncertainty range 7 026 852 to 28 714 867 to 4 575 937 to 844 021 to 1 457 934 to 23 244 283 to 981 935 to 5 260 654 to
9 315 473 38 649 243 6 313 709 1 235 194 2 069 514 32 609 187 1 337 970 7 184 664
Cost per 1 000 births
Direct medical costs 9 726 7 298 16 228 3 432 7 338 7 546 12 320 8 856
Nonmedical direct costs 392 59 500 588 548 1 000 1 166 511
Indirect costs 1 091 2 305 2 162 1 067 626 3 650 2 977 1 258
Total 11 209 9 662 18 889 5 086 8 513 12 196 16 463 10 625
DISCUSSION
The study demonstrates that rota-
virus gastroenteritis can be expected to
result in a large health and economic
burden in the eight Latin American
and Caribbean countries studied. For
every 1 000 children born, rotavirus
gastroenteritis was estimated to result
in an average of 246 outpatient visits,
24 hospitalizations, 0.6 deaths, and
2003 US$ 7 971 in direct medical costs
TABLE 5. Sensitivity analysis based on the effect of changes in rotavirus incidence and cost estimates on the total estimated economic
burden for the 2003 birth cohort in eight Latin American and Caribbean countries, expressed in 2003 US$ per 1 000 children for the first five
years of life
Dominican
Variable Argentina Brazil Chile Republic Honduras Mexico Panama Venezuela
Rotavirus hospitalization 
incidencea
–20% 10 078 8 499 17 162 4 714 8 168 11 896 15 451 9 992
Base case 11 209 9 662 18 889 5 086 8 513 12 196 16 463 10 625
+20% 12 340 10 825 20 617 5 458 8 858 12 496 17 476 11 259
Rotavirus outpatient 
incidence
–20% 10 098 8 893 16 839 4 440 7 155 10 057 14 183 9 134
Base case 11 209 9 662 18 889 5 086 8 513 12 196 16 463 10 625
+20% 12 320 10 432 20 940 5 732 9 871 14 335 18 744 12 117
Direct medical cost 
from hospitalizations
–20% 10 194 8 636 17 328 4 745 8 183 11 938 15 568 10 054
Base case 11 209 9 662 18 889 5 086 8 513 12 196 16 463 10 625
+20% 12 224 10 689 20 451 5 427 8 843 12 454 17 359 11 197
Direct medical cost 
from outpatient visits
–20% 10 279 9 229 17 206 4 741 7 375 10 945 14 895 9 425
Base case 11 209 9 662 18 889 5 086 8 513 12 196 16 463 10 625
+20% 12 139 10 096 20 573 5 431 9 651 13 447 18 032 11 825
a For each variable, the table shows the effect of a 20% increase or of a 20% decrease on the total economic burden of rotavirus gastroenteritis, compared to the baseline value.
TABLE 6. Cost and uncertainty range for the total estimated cost of rotavirus gastroenteritis in each country,  in 2003 US$, along with con-
tribution (percentage) of selected input variables to the variance in cost estimates for the 2003 birth cohort during the first five years of life
in eight Latin American and Caribbean countries 
Dominican
Argentina Brazil Chile Republic Honduras Mexico Panama Venezuela
Total cost (2003 US$) 8 137 641 33 537 642 5 402 388 1 032 454 1 753 684 27 750 765 1 152 441 6 183 961
Uncertainty range 7 026 852 to 28 714 867 to 4 575 937 to 844 021 to 1 457 934 to 23 244 283 to 981 935 to 5 260 654 to
(2003 US$) 9 315 473 38 649 243 6 313 709 1 235 194 2 069 514 32 609 187 1 337 970 7 184 664
Variables
Incidence of hospitalization 
for diarrhea 14% 17% 8% 10% 1% < 1% < 1% 4%
Incidence of hospitalization 
for rotavirus 13% 16% 8% 6% 2% < 1% 7% 4%
Incidence of outpatient 
visits for diarrhea 12% 20% 10% 33% 22% 28% 18% 22%
Incidence of outpatient 
visits for rotavirus 13% 7% 13% 21% 38% 51% 37% 22%
Direct medical costs 
from hospitalization 28% 15% 46% 23% 6% < 1% 3% 15%
Direct medical costs 
from outpatient visits 15% 4% 8% < 1% 25% 2% 12% 12%
Indirect costs from 
hospitalization < 1% 2% < 1% < 1% < 1% < 1% < 1% < 1%
Indirect costs from 
outpatient visits 4% 18% 7% 5% 4% 17% 10% 19%
during their first five years of life.
These rates translated into estimates of
approximately 2 000 000 outpatient
visits, 190 000 hospitalizations, 5 000
deaths, and US$ 62.4 million in direct
medical costs for the 2003 annual birth
cohort by the age of 5 years. Direct
medical expenses from hospitaliza-
tions and outpatient visits were pre-
dicted to account for costs of up to 
US$ 16 per child (US$ 3.4 to US$ 16.2,
depending on the country). When pro-
ductivity losses for caregivers and ad-
ditional out-of-pocket expenses were
also considered, the estimated societal
cost rose to almost US$ 19 per child
(US$ 5.1 to US$ 18.9, depending on the
country). For the eight countries to-
gether, rotavirus gastroenteritis was
estimated to lead to costs of US$ 85
million (including societal costs) for
the 2003 birth cohort. This estimate did
not include additional costs associated
with cases that are treated at home or
by traditional healers and pharmacists. 
The estimated number of deaths 
due to rotavirus in the current study 
is lower than the estimates by Para-
shar and colleagues, which were based
on regression analysis rather than
country-specific data (1). The observed
differences were greatest for Chile, Ar-
gentina, and Mexico, all of which are
upper-middle-income countries. Be-
cause most of the studies used in Para-
shar’s regression model were from
low-income and lower-middle-income
countries (1), their model may not per-
form as accurately for higher-income
countries. 
In terms of public health, deaths and
hospitalizations for severe cases of gas-
troenteritis are of greatest concern.
However, from an economic perspec-
tive, outpatient visits are also of con-
cern since they can generate a large
portion of the costs of rotavirus gastro-
enteritis. Outpatient visits accounted
for an estimated 30% to 83% of the di-
rect medical costs in each country, and
accounted for an even greater fraction
of the total estimated societal costs
(40% to 88%). The proportion of total
costs associated with outpatient visits
was higher in countries with lower
rates of rotavirus hospitalizations,
such as Mexico and Honduras. 
Rotavirus gastroenteritis was pre-
dicted to result in substantial disease
and economic burdens in each of the
eight countries studied; however, the
pattern differed slightly among coun-
tries. As expected, the greatest disease
burden (in terms of DALYs ) was pre-
dicted for lower-middle-income coun-
tries, especially the Dominican Repub-
lic and Honduras. In contrast, the
greatest economic burden was fore-
seen in upper-middle-income coun-
tries due to their higher treatment
costs per child and higher productivity
losses. Variability in health care costs
may be due to differences in treatment
patterns (medications, diagnostics,
and relative importance of inpatient
and outpatient treatment) and input
costs (primarily labor). 
Figure 2 shows the predicted health
and economic burdens of rotavirus
(DALYs per 1 000 births and total cost
per child) by per-capita income in each
of the countries. Although higher-in-
come countries tended to have higher
economic burdens, and lower-income
countries tended to have higher health
burdens, many middle-income coun-
tries had large health and economic
burdens associated with rotavirus gas-
troenteritis. This may reflect real dif-
ferences between countries. For chil-
dren who have access to timely
medical attention, rotavirus gastroen-
teritis is likely to generate economic
costs. For children with little access to
medical care, gastroenteritis may be
more likely to result in mortality (an
increase in DALYs ).
The sensitivity and uncertainty
analyses provide an important tool for
assessing the validity of the burden es-
timates presented here. Although
there is uncertainty about the country-
specific epidemiological and economic
inputs used in the model, the overall
uncertainty bounds presented in Table
4 suggest that the economic burden es-
timates are quite robust. In countries
where uncertainty bounds are wider,
estimates could be improved with ad-
ditional data for input variables that
contribute the most to overall uncer-
tainty. This is particularly true for
countries where epidemiological esti-
mates were extrapolated from other
countries. 
FIGURE 2. Estimated economic and health burden of rotavirus diarrhea for the 2003 birth
cohort in eight selected Latin American and Caribbean countries, by per capita gross do-
mestic product (GDP), as measured in disability-adjusted life years (DALYs)/1 000 children
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The primary limitations of this study
relate to the availability of country-
specific incidence data for severe ro-
tavirus gastroenteritis events. The po-
tential impact of these data limitations
was systematically assessed in the sen-
sitivity and uncertainty analyses to
determine their importance. Another
limitation is that the study did not in-
clude the costs borne by families for
treatment of rotavirus gastroenteri-
tis in less formal settings, including
treatment at home or by traditional
healers. As a result, the estimates pre-
sented here are likely to underestimate
the total economic burden of rotavirus
gastroenteritis.
The evidence presented in this
study lends support to the conclusion
that rotavirus gastroenteritis can be
expected to produce substantial mor-
bidity, mortality, and health care sys-
tem costs in Latin America and the
Caribbean. For every 1 000 children
born in 2003, we estimate that ro-
tavirus will result in 246 outpatient
visits, 24 hospitalizations, 0.6 deaths,
and US$ 7 971 in direct medical costs
during their first five years of life. The
eight countries studied here may
spend an estimated total US$ 62.4 mil-
lion annually in direct medical costs
arising from the treatment of rotavirus
gastroenteritis. When the costs of
transportation and time lost from
work are included, the total estimated
societal burden of rotavirus gastroen-
teritis is approximately US$ 86 million
for the eight countries. This estimate
does not include the additional non-
medical costs borne by families, or the
costs of treatment in less formal set-
tings, which may comprise an impor-
tant proportion of the total economic
burden imposed by rotavirus. Al-
though rotavirus is often described as
a democratic virus because it infects al-
most all children by the age of 5 years,
the nature of the resulting burden can
differ greatly. In higher-income coun-
tries the economic burden is likely to
be greater, whereas in lower-income
countries it is the health burden that
can be expected to be greater. 
As vaccines become available to
control rotavirus gastroenteritis, infor-
mation on the economic and health
burden of disease in Latin America
and the Caribbean, as well as in other
regions, becomes more important.
Health care resources used to treat ro-
tavirus gastroenteritis could be used to
address other health challenges or to
offset the costs of vaccination. These
economic burden estimates provide
the foundation for further evaluations
of the cost-effectiveness of rotavirus
vaccination.
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Objetivo. Estimar la carga económica y de morbilidad de la gastroenteritis por ro-
tavirus en hospitales y servicios ambulatorios de ocho países de América Latina y el
Caribe (Argentina, Brasil, Chile, Honduras, México, Panamá, República Dominicana
y Venezuela).
Métodos. Se elaboró un modelo económico a partir de datos epidemiológicos de ar-
tículos publicados, estudios de autoridades sanitarias nacionales y los estimados de
costos específicos de cada país. El modelo calculó las consecuencias de la infección
por rotavirus en los primeros cinco años de vida de la cohorte de nacidos en 2003 en
cada uno de los ocho países estudiados. Las principales medidas de valoración fueron
los costos de la atención sanitaria, los costos de transportación, los salarios perdidos
y la carga de morbilidad expresada en años de vida ajustados por discapacidad. Los
estimados se expresaron en dólares estadounidenses del año 2003. Se empleó una tasa
de descuento de 3% para los cálculos de costos y años de vida ajustados por discapa-
cidad de los años siguientes. El impacto de las variables específicas sobre los costos
clínicos del tratamiento de la infección por rotavirus se realizó mediante análisis de
sensibilidad.
Resultados. Se estimó que durante los primeros cinco años de vida, la gastroenteri-
tis por rotavirus provoca en promedio 246 consultas externas, 24 hospitalizaciones,
0,6 muertes y gastos médicos directos por US$ 7 971,00 por cada 1 000 niños nacidos
en 2003 en los ocho países estudiados de América Latina y el Caribe. Se prevé que la
frecuencia de visitas médicas asociadas con la infección por rotavirus y los costos por
consultas externas tengan el mayor impacto en los costos clínicos totales por niño.
Conclusiones. La gastroenteritis por rotavirus puede representar una considerable
carga económica y de morbilidad para los sistemas sanitarios de los países de Amé-
rica Latina y el Caribe. Se debe prestar una especial atención a la carga previsible al
evaluar la efectividad en función del costo de la vacunación contra rotavirus. 
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